Skip to main content

Tricyclic Antidepressants

Tricyclic antidepressants (TCAs) have several pharmacologic effects relevant to pain, sleep and the lower urinary tract, but the evidence differs greatly by indication. Amitriptyline is an AUA oral option for IC/BPS (Grade B). Imipramine has a US-labeled temporary adjunctive role in childhood enuresis from age 6. Historical reports of OAB, SUI and nonspecific pelvic symptoms do not establish routine efficacy. Low-dose doxepin is labeled for sleep-maintenance insomnia, not nocturia.[1][2][18]

For class-comparison context see SNRIs and Gabapentinoids. For the conditions these agents target, see IC/PBS, Chronic Pelvic Pain, and Nocturia.

Mechanism — Why TCAs Are Multifunctional in the LUT​

MechanismLUT effect
Antimuscarinic (competitive M-receptor antagonism)Reduces involuntary detrusor contractions and increases capacity. Imipramine, amitriptyline, nortriptyline, clomipramine all competitively antagonize ACh-induced bladder smooth-muscle contractions in isolated-tissue experiments; these data do not establish clinical benefit for each LUT indication[3][4][5]
5-HT and NE reuptake inhibitionModulates the micturition reflex at spinal and supraspinal levels. In rat experiments, acute imipramine raises the spinal reflex threshold (serotonergic), while chronic dosing raises the supraspinal threshold via a separate mechanism[6]
Direct smooth-muscle relaxationImipramine inhibits both bethanechol- and barium chloride–induced contractions — independent of antimuscarinic effect[5]
Norepinephrine reuptake at bladder neck / urethraIncreases urethral closure pressure → potentially useful for SUI, harmful in voiding dysfunction[7][8][9]
Sodium channel blockadeLocal-anesthetic effect on bladder afferent nerves — relevant to IC/BPS pain
Central sleep / arousal modulationSleep/arousal effects have been proposed, but the mechanism of enuresis benefit is not established[10][11]

Agent comparison​

AgentPrimary urologic roleAnticholinergic potencyFDA urologic indication
ImipramineEnuresis; OAB/SUI use is historical and weakly supportedModerateYes — childhood enuresis[2]
AmitriptylineIC/BPS; selected neuropathic painHighest among TCAsNo
NortriptylineSelected neuropathic pain; historical frequency studiesLower than amitriptylineNo[16]
DoxepinInsomnia at low dose; historical DO studiesModerate; potent antihistamineYes for insomnia at 3–6 mg (not urologic)[18]
DesipramineNeuropathic CPP componentLowest of the TCAsNo
Clomipramine(Adverse-effect concern: urinary retention)HighNo

IC/BPS — the most evidence-based urologic application​

The 2022 AUA IC/BPS Guideline lists amitriptyline as an oral medication option (Statement 14) — alphabetically alongside cimetidine, hydroxyzine, and pentosan polysulfate, with no hierarchy. Evidence Strength Grade B.[1][20]

Mechanism in IC/BPS​

Amitriptyline's stacked effects fit IC/BPS particularly well — antimuscarinic for urgency/frequency, central + peripheral analgesia for pain, antihistamine effect on mast-cell-mediated pathophysiology, and sedation that improves nocturia-disrupted sleep.[20]

Pivotal RCT — van Ophoven 2004​

50 patients, prospective placebo-controlled double-blind, amitriptyline self-titrated 25 mg weekly to max 100 mg/day × 4 months:[14]

  • Mean combined O’Leary–Sant symptom/problem score 26.9 → 18.5 (amitriptyline) vs 27.6 → 24.1 (placebo) — p = 0.005
  • Pain and urgency intensity improved significantly (p < 0.001)
  • Anticholinergic AEs in 92%

Treatment-naïve RCT — Foster 2010​

Multicenter (n = 271 treatment-naïve), amitriptyline 10 → 75 mg/day × 6 weeks + standardized education / behavioral modification, 12-week follow-up:[21]

  • Primary endpoint (moderate/marked GRA): 55% vs 45% (p = 0.12) — not significant
  • Subgroup achieving ≥ 50 mg/day (n = 207): 66% vs 47% (p = 0.01) — an unplanned subgroup analysis, influenced by dose tolerance and adherence; it does not establish a mandatory efficacy threshold

Network meta-analysis 2021​

ICSI significantly reduced vs placebo (MD −4.9, 95% CI −9.0 to −0.76); amitriptyline had a favorable symptom-score estimate. Network ranking does not establish a treatment hierarchy, and certolizumab remains investigational for IC/BPS.[22]

AUA dosing​

Start 10 mg QHS; titrate according to benefit and tolerability, with 75–100 mg/day as the upper range discussed in the guideline, not a required target. Anticholinergic AEs are common (sedation, drowsiness, nausea) and frequently QoL-limiting.[1]

Nocturnal Enuresis — the only FDA-approved urologic indication​

Imipramine is FDA-approved as adjunctive therapy for nocturnal enuresis in children ≥ 6 years after organic causes are excluded.[2]

Dosing and monitoring​

Use the imipramine hub for age- and weight-limited dosing, ECG assessment and secure storage. The age-specific dose ceiling and 2.5 mg/kg/day limit both apply; long-term uninterrupted use is not established by the label.[2]

Cochrane 2016 evidence (64 trials, 4,071 children)[10][11]​

  • ~ 1 fewer wet night per week vs placebo (MD −0.95)
  • About 1 in 5 children become dry on imipramine
  • 78% fail to achieve 14 consecutive dry nights on imipramine vs 95% on placebo (RR 0.74)
  • Imipramine + oxybutynin more effective than placebo (33% vs 78% failure to achieve 14 dry nights; RR 0.43)
  • High relapse on discontinuation

Safety[11][23]​

  • Cardiotoxicity — arrhythmias, QT prolongation; obtain baseline ECG
  • Overdose lethality — TCAs are among the most dangerous drugs in overdose; ICCS recommends imipramine only after all other therapies have failed
  • Mood changes and sleep disturbance common
  • Store securely away from younger siblings

Current role​

A specialist option after adequate alarm therapy and desmopressin have failed; combination treatment requires individual assessment of the additional anticholinergic burden.[11][23]

OAB / Detrusor Overactivity​

TCAs reduce detrusor overactivity through three convergent mechanisms — antimuscarinic blockade, direct smooth-muscle relaxation, and central modulation of the micturition reflex.[7][24]

Selected evidence​

  • Castleden 1981 — a historical uncontrolled study of high-dose imipramine in 10 elderly patients (not a current prescribing template) with unstable detrusor: continence in 6/10 (60%), with mean +105 mL capacity, −18 cm H₂O bladder pressure at capacity, +30 cm H₂O urethral pressure[9]
  • Lose 1989 (doxepin) — double-blind crossover RCT in 19 women with detrusor overactivity refractory to conventional therapy; doxepin 50 mg QHS ± 25 mg AM significantly decreased nighttime micturitions and nighttime incontinence episodes[17]
  • Servadio 1975 (nortriptyline) — open study in 40 women with chronic frequency, urgency, dysuria; nortriptyline produced considerable improvement or total resolution in 75%; in vitro confirmed antimuscarinic activity[15]

Current role​

TCAs are not standard OAB pharmacotherapy. Modern antimuscarinics and β3-agonists have stronger direct evidence. A separate pain or psychiatric indication does not prove that adding a TCA will improve OAB.[24][25][26][27]

Stress and Mixed Urinary Incontinence​

Imipramine's NE-reuptake inhibition at the bladder neck and proximal urethra raises urethral closure pressure — the rationale for its off-label SUI use.[7][8][28][29]

Evidence​

  • Gilja 1984 — 30 women with SUI on imipramine 75 mg/day × 4 weeks: continence in 21/30 (71%); functional urethral length extended and stress-resistant in responders[8]
  • A 2019 randomized crossover study in 16 healthy women found no significant or clinically relevant urethral-pressure increase after a single 50 mg imipramine dose. This was a surrogate experiment, not a therapeutic trial in women with SUI; convincing randomized clinical efficacy is lacking.[40]

Mixed incontinence​

The dual antimuscarinic + noradrenergic profile theoretically covers urge and stress components — but no head-to-head data support this in mixed UI.[28]

Comparison with duloxetine​

Duloxetine belongs to the SNRI class, not the TCAs. It has Phase III SUI evidence and a European SUI indication, but is not FDA-approved for SUI. See the SNRI hub for benefit–harm counseling; imipramine is not an evidence-equivalent substitute.[28][29]

CP/CPPS​

TCAs are part of the "N" (Neurologic / Systemic) domain of the UPOINT system for CP/CPPS — used for the neuropathic-pain component when present.[31]

  • Cochrane 2019: antidepressants (including TCAs) may be ineffective for prostatitis-symptom reduction (low- to very-low-quality evidence); GI discomfort, decreased libido, ejaculatory disorders, sedation, and dizziness were common AEs[30]
  • UPOINT-directed cohort studies report improvements with multimodal care, but cannot isolate the contribution of TCAs[31]
  • Real-world prescribing pattern: in the Agarwal UCPPS comparison, 13.6% of gabapentin patients required adjunctive amitriptyline vs 44% of pregabalin patients (p = 0.0001) — a retrospective prescribing observation, not evidence of a superior drug sequence[32]
  • TCAs are not first-line monotherapy; use as part of multimodal phenotype-directed therapy when neuropathic features, sleep disturbance, or comorbid depression are present[33]

Chronic Pelvic Pain in Women​

ACOG (2020) recognizes TCAs as commonly used for neuropathic pain but cites only weak evidence for CPP specifically. SNRIs are favored at Level B for neuropathic CPP. A 2009 RCT showed gabapentin + nortriptyline outperformed either alone for neuropathic pain.[12]

The 2021 JAMA CPP review concludes TCAs "help with associated mood, sleep, and neuropathic pain symptoms and may in turn improve quality of life but only provide minimal improvements in pain."[13]

Practical: pelvic pain does not itself establish a neuropathic indication. For a confirmed neuropathic pain disorder, NICE lists amitriptyline, duloxetine, gabapentin or pregabalin as initial choices; no universal TCA-after-SNRI sequence is established. The cited combination trial involved diabetic neuropathy or postherpetic neuralgia, not pelvic pain.[41][12][13]

Nocturia and historical nonspecific LUT symptoms​

Doxepin 3–6 mg is FDA-approved for sleep-maintenance insomnia. Its insomnia trials do not establish treatment efficacy for nocturia. Assess nocturnal urine production, bladder symptoms, sleep apnea and primary insomnia separately; a hypnotic is not a substitute for identifying why the patient wakes to void. Low-dose doxepin is contraindicated with severe urinary retention or untreated narrow-angle glaucoma and is ordinarily not recommended in severe sleep apnea.[18][34][35][37]

The 2004 amitriptyline IC/BPS trial did not significantly improve frequency or functional capacity versus placebo. A separate 22-person retrospective series reported improvement in nonspecific frequency/pain, but it does not validate a new diagnostic phenotype or establish indefinite maintenance therapy.[14][36]

Urologic Adverse Effects — under-recognized​

TCAs produce significant urologic AEs that matter both as treatment limitations and as diagnostic considerations when patients on TCAs present with new urinary symptoms.

Urinary retention is the most common urologic ADR​

  • A pharmacovigilance study (462,661 psychiatric inpatients, 1993–2016): urinary retention was the most common urologic ADR of psychotropics; TCAs had higher risk than SSRIs; amitriptyline and clomipramine were the most common TCA culprits[19]
  • Systematic review and meta-analysis: Antidepressants overall, not TCAs alone, were associated with more voiding disorders than placebo: OR 3.30 (95% CI 1.90–5.72)[38]

FDA-label urologic / sexual / endocrine effects (TCA class)[16][2][39]​

  • Urinary retention; delayed micturition; urinary tract dilation; paradoxical frequency at low doses
  • Decreased or increased libido; erectile dysfunction; testicular swelling; ejaculatory disorders; gynecomastia in males
  • SIADH / hyponatremia — reported with all TCAs; clinically significant in elderly patients on diuretics; the amitriptyline label specifically warns about SIADH-related hyponatremia
  • Cardiovascular — QT prolongation, arrhythmias, heart block; obtain baseline ECG. Secondary amines may have lower relative anticholinergic effects, but nortriptyline and desipramine are still listed as strongly anticholinergic drugs to avoid in most older adults by Beers[42][16]

Practical prescribing and clinical positioning​

  • IC/BPS: amitriptyline is an option, with low-dose initiation and individualized titration. The negative overall Foster trial and its unplanned higher-dose subgroup must both be discussed; do not escalate solely to cross a supposed 50 mg efficacy threshold.[1][21]
  • Enuresis: imipramine has a temporary adjunctive indication, but relapse is common and cardiotoxicity/overdose risk reserve it for specialist use after safer established approaches. See the dedicated hub for dosing.[2][10][11]
  • Other pelvic pain: AUA 2025 permits neuropathic-pain drug classes for selected men with chronic pelvic pain (Conditional / Grade C); response and functional benefit require reassessment. General neuropathic-pain guidance does not establish efficacy for every pelvic-pain phenotype.[41][43]
  • OAB/SUI/nocturia: historical small studies and mechanistic reasoning do not justify a routine TCA prescribing regimen.[9][17][40]

Safety before and during treatment​

TCAs can cause retention, constipation, cognitive impairment, orthostatic symptoms and cardiac conduction toxicity. Assess cardiac history and interacting medicines; ECG monitoring should reflect age, cardiac risk, dose and the specific product. Acute post-MI use is contraindicated or not recommended depending on the TCA label. Avoid MAOI combinations and observe the product’s washout instructions, including special precautions with linezolid or IV methylene blue. Monitor mood, suicidality and possible bipolar activation; antidepressant labels carry a suicidality boxed warning. Prescribe limited quantities when overdose risk exists and taper when stopping.[2][16][39]

A lower relative anticholinergic effect does not make nortriptyline or desipramine safe by default in an older patient. Beers includes both, alongside amitriptyline and imipramine, among strongly anticholinergic antidepressants; doxepin ≤6 mg/day is the low-dose exception, used for insomnia with its own precautions.[18][42]

See Also​

References​

1. Clemens JQ, Erickson DR, Varela NP, Lai HH. "Diagnosis and treatment of interstitial cystitis/bladder pain syndrome." J Urol. 2022;208(1):34–42. doi:10.1097/JU.0000000000002756

2. DailyMed. Imipramine hydrochloride: prescribing information. Label. Accessed September 12, 2026.

3. Uno J, Obara K, Suzuki H, et al. "Inhibitory effects of antidepressants on acetylcholine-induced contractions in isolated guinea pig urinary bladder smooth muscle." Pharmacology. 2017;99(1-2):89–98. doi:10.1159/000452221

4. Rehavi M, Weiss H, Nissenkorn I, Rubinstein R, Cohen S. "A comparative study of the affinities of some tricyclic antidepressants for the muscarinic cholinergic receptor in human and guinea-pig bladder, ileum and brain in relation to differential drug potency." Life Sci. 1987;40(18):1819–1827. doi:10.1016/0024-3205(87)90093-2

5. Benson GS, Sarshik SA, Raezer DM, Wein AJ. "Bladder muscle contractility: comparative effects and mechanisms of action of atropine, propantheline, flavoxate, and imipramine." Urology. 1977;9(1):31–35. doi:10.1016/0090-4295(77)90279-5

6. Maggi CA, Borsini F, Lecci A, et al. "Effect of acute or chronic administration of imipramine on spinal and supraspinal micturition reflexes in rats." J Pharmacol Exp Ther. 1989;248(1):278–285.

7. Sullivan J, Abrams P. "Pharmacological management of incontinence." Eur Urol. 1999;36(Suppl 1):89–95. doi:10.1159/000052327

8. Gilja I, Radej M, Kovacić M, Parazajder J. "Conservative treatment of female stress incontinence with imipramine." J Urol. 1984;132(5):909–911. doi:10.1016/s0022-5347(17)49941-1

9. Castleden CM, George CF, Renwick AG, Asher MJ. "Imipramine — a possible alternative to current therapy for urinary incontinence in the elderly." J Urol. 1981;125(3):318–320. doi:10.1016/s0022-5347(17)55023-5

10. Caldwell PHY, Sureshkumar P, Wong WCF. Tricyclic and related drugs for nocturnal enuresis in children. Cochrane Database Syst Rev. 2016;1:CD002117. doi:10.1002/14651858.CD002117.pub2.

11. Robson WL. "Evaluation and management of enuresis." N Engl J Med. 2009;360(14):1429–1436. doi:10.1056/NEJMcp0808009

12. American College of Obstetricians and Gynecologists. "Chronic pelvic pain: ACOG Practice Bulletin, Number 218." Obstet Gynecol. 2020;135(3):e98–e109. doi:10.1097/AOG.0000000000003716

13. Lamvu G, Carrillo J, Ouyang C, Rapkin A. "Chronic pelvic pain in women: a review." JAMA. 2021;325(23):2381–2391. doi:10.1001/jama.2021.2631

14. van Ophoven A, Pokupic S, Heinecke A, Hertle L. "A prospective, randomized, placebo controlled, double-blind study of amitriptyline for the treatment of interstitial cystitis." J Urol. 2004;172(2):533–536. doi:10.1097/01.ju.0000132388.54703.4d

15. Servadio C, Nissenkorn I, Zeigler M. "Nortriptyline hydrochloride in urology." Urology. 1975;5(6):747–750. doi:10.1016/0090-4295(75)90345-3

16. DailyMed. Nortriptyline hydrochloride: prescribing information. Label. Accessed September 12, 2026.

17. Lose G, Jørgensen L, Thunedborg P. "Doxepin in the treatment of female detrusor overactivity: a randomized double-blind crossover study." J Urol. 1989;142(4):1024–1026. doi:10.1016/s0022-5347(17)38976-0

18. Currax. SILENOR (doxepin): prescribing information. DailyMed. Accessed September 12, 2026.

19. Winkler D, Grohmann R, Friedrich ME, et al. "Urological adverse drug reactions of psychotropic medication in psychiatric inpatients — a drug surveillance report from German-speaking countries." J Psychiatr Res. 2021;144:412–420. doi:10.1016/j.jpsychires.2021.10.026

20. Chermansky CJ, Guirguis MO. "Pharmacologic management of interstitial cystitis / bladder pain syndrome." Urol Clin North Am. 2022;49(2):273–282. doi:10.1016/j.ucl.2022.01.003

21. Foster HE, Hanno PM, Nickel JC, et al. "Effect of amitriptyline on symptoms in treatment naïve patients with interstitial cystitis / painful bladder syndrome." J Urol. 2010;183(5):1853–1858. doi:10.1016/j.juro.2009.12.106

22. Di XP, Luo DY, Jin X, et al. "Efficacy and safety comparison of pharmacotherapies for interstitial cystitis and bladder pain syndrome: a systematic review and Bayesian network meta-analysis." Int Urogynecol J. 2021;32(5):1129–1141. doi:10.1007/s00192-020-04659-w

23. Lauters RA, Garcia KW, Arnold JJ. "Enuresis in children: common questions and answers." Am Fam Physician. 2022;106(5):549–556.

24. Andersson KE. "Treatment of overactive bladder: other drug mechanisms." Urology. 2000;55(5A Suppl):51–57. doi:10.1016/s0090-4295(99)00495-1

25. Wein AJ. "Pharmacologic options for the overactive bladder." Urology. 1998;51(2A Suppl):43–47. doi:10.1016/s0090-4295(98)90009-7

26. Athanasopoulos A. "The pharmacotherapy of overactive bladder." Expert Opin Pharmacother. 2011;12(7):1003–1005. doi:10.1517/14656566.2011.554397

27. Loloi J, Clearwater W, Schulz A, Suadicani SO, Abraham N. "Medical treatment of overactive bladder." Urol Clin North Am. 2022;49(2):249–261. doi:10.1016/j.ucl.2021.12.005

28. Norton P, Brubaker L. "Urinary incontinence in women." Lancet. 2006;367(9504):57–67. doi:10.1016/S0140-6736(06)67925-7

29. Wu JM. "Stress incontinence in women." N Engl J Med. 2021;384(25):2428–2436. doi:10.1056/NEJMcp1914037

30. Franco JV, Turk T, Jung JH, et al. "Pharmacological interventions for treating chronic prostatitis / chronic pelvic pain syndrome." Cochrane Database Syst Rev. 2019;10:CD012552. doi:10.1002/14651858.CD012552.pub2

31. Polackwich AS, Shoskes DA. "Chronic prostatitis / chronic pelvic pain syndrome: a review of evaluation and therapy." Prostate Cancer Prostatic Dis. 2016;19(2):132–138. doi:10.1038/pcan.2016.8

32. Agarwal MM, Elsi Sy M. "Gabapentenoids in pain management in urological chronic pelvic pain syndrome: gabapentin or pregabalin?" Neurourol Urodyn. 2017;36(8):2028–2033. doi:10.1002/nau.23225

33. Pena VN, Engel N, Gabrielson AT, Rabinowitz MJ, Herati AS. "Diagnostic and management strategies for patients with chronic prostatitis and chronic pelvic pain syndrome." Drugs Aging. 2021;38(10):845–886. doi:10.1007/s40266-021-00890-2

34. Morin CM, Buysse DJ. "Management of insomnia." N Engl J Med. 2024;391(3):247–258. doi:10.1056/NEJMcp2305655

35. Morin CM, Benca R. "Chronic insomnia." Lancet. 2012;379(9821):1129–1141. doi:10.1016/S0140-6736(11)60750-2

36. Pranikoff K, Constantino G. "The use of amitriptyline in patients with urinary frequency and pain." Urology. 1998;51(5A Suppl):179–181. doi:10.1016/s0090-4295(98)00071-5

37. Kim J, Chung E. "Pharmacotherapeutic options in the treatment of nocturia: an update on the current oral drug therapies." Expert Opin Pharmacother. 2022;23(3):405–411. doi:10.1080/14656566.2021.2016698

38. Trinchieri M, Perletti G, Magri V, et al. "Urinary side effects of psychotropic drugs: a systematic review and metanalysis." Neurourol Urodyn. 2021;40(6):1333–1348. doi:10.1002/nau.24695

39. DailyMed. Amitriptyline hydrochloride: prescribing information. Label. Accessed September 12, 2026.

40. Kornholt J, Sonne DP, Riis T, Sonne J, Klarskov N. Effect of imipramine on urethral opening pressure: a randomized, double-blind, placebo-controlled crossover study in healthy women. Neurourol Urodyn. 2019;38:1076–1080. doi:10.1002/nau.23955.

41. NICE. Neuropathic pain in adults: pharmacological management (CG173). Recommendations.

42. American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria. J Am Geriatr Soc. 2023;71:2052–2081. doi:10.1111/jgs.18372.

43. American Urological Association. Diagnosis and Management of Male Chronic Pelvic Pain. 2025. Full guideline.